Early-stage Alzheimer’s Disease Study
PMG Research of McFarland Clinic
60 - 85
A diagnosis of dementia caused by Alzheimer’s disease can be difficult to battle for all involved. This neurological disease accounts for about 80% of all dementia cases. As cognitive abilities and memory loss progress, it hinders normal daily tasks and lowers quality of life. Most with Alzheimer’s disease eventually require 24 hour care from skilled caregivers. Identifying genetic markers and evaluating age-related risks, is one way to catch the disease in its early stages. Starting treatments early can slow the progression, but currently there is no cure. Researchers are developing new treatments that may help those with early stages of Alzheimer’s disease.
Accellacare is currently enrolling volunteers in a study that is evaluating an investigational medication’s ability to address symptoms of early Alzheimer’s disease.
This study may be an option if you or a loved one:
- Is between the ages of 60 – 85 years of age
- Has a gradual progression of dementia caused by Alzheimer’s disease
- Has a reliable study partner available to attend study visits
- Has no other neurological disease other than Alzheimer’s disease
Other criteria apply.
Eligible participants will receive study-related care and study medication at no cost.
Patient Commitment Duration
about 1 year
Financial compensation will also be provided for time and travel expenses.
Number of visits in study
about 14 clinic visits